Plasticell increases flow of stem cell therapy pipeline

Plasticell founder named “Best CEO in the Stem Cell industry” by European CEO magazine Plasticell, a developer of stem cell technologies and cell-based therapies, has announced that the Company’s founder, Dr. Yen Choo, has been named “Best CEO in the Stem Cell Industry” by European CEO magazine.  This accolade in part recognises Plasticell’s success in organic growth as well as [...]

February 7th, 2017|Press Releases|

Published scientific data demonstrates Plasticell’s CombiCult® technology platform expands stem cells in umbilical cord blood

Plasticell, a leader in high throughput technology to develop stem cell therapies in regenerative medicine, has announced the publication of peer-reviewed scientific research in the journal Stem Cells and Development, which demonstrates how the company’s award-winning platform technology can be used to discover novel cell culture protocols that expand specific populations of therapeutic stem cells present in cord blood. Hematopoietic stem [...]

November 22nd, 2016|Press Releases|

Plasticell completes £1.32 million financing to advance therapeutic projects

Plasticell, the biotechnology company specialising in cell and gene therapy research, announces the completion of a two-part equity financing round, raising a total of £1.32 million from its shareholders and new investors. The investment will provide capital to progress the company’s therapeutic programmes, including the expansion of hematopoietic stem cells and in vitro manufacturing of blood products such as platelets, [...]

November 4th, 2016|Press Releases|

Plasticell and CellSpring collaborate to validate osteogenic cell therapy and 3D cell culture models for high performance drug screening

Plasticell, the biotechnology company using combinatorial technologies for stem cell research and optimization of cell and gene therapy manufacturing, has announced it is collaborating with CellSpring, an innovative company that has developed a high throughput 3D cell culture system, the 3D Bloom® Biopolymer Platform, which enables more informed “stop/go” decisions for preclinical candidates. Plasticell and CellSpring are developing tissue [...]

September 19th, 2016|Press Releases|

Plasticell and National University of Ireland initiate cancer stem cell collaboration

Plasticell, the biotechnology company using combinatorial technologies for stem cell research and the optimization of cell and gene therapy manufacturing, has announced the signing of a collaboration agreement with the National University of Ireland, Galway (NUI Galway) focused on methods of eradicating cancer stem cells. Many malignant tumors are initiated and maintained by a discrete population of tumour cells that [...]

August 2nd, 2016|Press Releases|

Plasticell awarded the Queen’s Award for Enterprise in Innovation

Plasticell is pleased to announce it has been awarded the 2016 Queen’s Award for Enterprise in Innovation. The award is the UK’s highest accolade for outstanding commercial success as a result of innovation in recognition of Plasticell’s contribution to the advancement of regenerative medicine, cell and gene therapy as well as other areas of biomedical research. Dr. Yen Choo, Plasticell’s founder and Executive Chairman, will [...]

April 21st, 2016|Press Releases|

Plasticell and Sphere Fluidics sign research collaboration to develop gene transduction technology leading to safer and more efficient gene therapies

Plasticell, a biotechnology company using combinatorial cell culture technologies for optimization of cell and gene therapy manufacturing, has announced the signing of a collaboration agreement with Sphere Fluidics, a company specializing in single cell encapsulation and screening. Plasticell has used its proprietary Combinatorial Cell Culture™ (CombiCult®) platform to develop inexpensive, high-efficiency gene transduction protocols as alternatives to costly commercial transfection [...]

March 29th, 2016|Press Releases|

Plasticell and Pierre Fabre Laboratories sign a partnership to identify natural stimulants of brown fat for treatment and prevention of obesity and diabetes

Plasticell, the biotechnology company specializing in stem cell differentiation, and Pierre Fabre, the 2ndlargest independent French Pharmaceutical laboratory, have today announced the signing of a collaboration agreement. The two companies will work together to discover plant-based products that enhance the metabolic function of brown adipose tissue (BAT) – also known as ‘brown fat’. Plasticell will screen Pierre Fabre’s ‘Nature Open [...]

February 23rd, 2016|Press Releases|

Plasticell appoints Dr Aaron T. T. Chuang as Chief Scientific Officer

Plasticell, the regenerative medicine company utilising its award-winning combinatorial technologies for stem cell research and in developing cell therapies, has recruited Dr Aaron Chuang to its executive management team in the role of Chief Scientific Officer (CSO). Prior to this appointment, Dr Chuang served as Research Director at the Regenerative Medicine unit of GlaxoSmithKline (GSK), where he worked for over 18 years. As Plasticell’s CSO, Dr Chuang [...]

June 15th, 2015|Press Releases|

Plasticell wins Innovate UK funding for £1.6 million cord blood stem cell manufacturing project

Plasticell has announced that Innovate UK has made a further investment in a therapeutic programme utilising CombiCult®, the high throughput stem cell technology designed to solve bottlenecks in regenerative medicine development Innovate UK will provide a grant of approximately £1.3 million to a research consortium led by Plasticell for a project entitled ‘Ex-vivo expansion of cord blood and bone marrow [...]

February 5th, 2015|Press Releases|

Peer-reviewed scientific publication highlighting CombiCult® technology demonstrates power of massively parallel stem cell differentiation

Plasticell Limited announced today the publication of peer-reviewed scientific research that demonstrates how the company’s proprietary ‘Combinatorial Cell Culture™‘ (CombiCult®) technology allows scientists to perform and compare 10,000 embryonic stem cell differentiation experiments in parallel. The individual experiments would have required around 200 years to complete back-to-back. The paper entitled ‘Directed differentiation of embryonic stem cells using a bead-based combinatorial [...]

September 25th, 2014|Press Releases|

Plasticell spin-out, Progenitor Labs, named a Finalist for the 2014 Red Herring Top 100 Europe Award

Progenitor Labs, the biotech company developing small molecule drugs to regenerate organs of the body, announced today it has been selected a Red Herring Top 100 Europe Finalist, a prestigious list honoring the year’s most promising private technology ventures from the European business region. The Red Herring editorial team selected the most innovative companies from a pool of hundreds in [...]

March 25th, 2014|Press Releases|

Plasticell signs deal with JCR Pharmaceuticals to use CombiCult® stem cell technology in Japan

Plasticell, the biotechnology company specializing in stem cell differentiation, has today announced that it has signed a collaboration agreement with JCR Pharmaceuticals Co., Ltd. of Ashiya, Hyogo Pref., Japan, to discover custom stem cell culture media using its award-winning combinatorial stem cell technology, CombiCult®. Under the terms of the agreement, Plasticell will use its stem cell expertise to work with [...]

February 24th, 2014|Press Releases|

Additional family of CombiCult® patents granted in USA, Europe, Australia and Singapore

Plasticell, the biotechnology company developing regenerative drugs using high throughput stem cell technologies, has announced that a further family of patents, offering additional protection of its proprietary cell culture technology, Combinatorial Cell Culture™ (CombiCult®), have been granted by the US Patent Office, European Patent Office, Australian Patent Office and Intellectual Property Office of Singapore. The newly granted patents cover the use of nanomaterial tags [...]

November 11th, 2013|Press Releases|

Plasticell and Progenitor Labs seed cell therapy activities at the Stevenage Bioscience Catalyst open innovation campus

Stevenage Bioscience Catalyst (SBC), the UK’s first open innovation bioscience campus, is pleased to welcome regenerative medicine companies Plasticell Ltd and Progenitor Labs as tenants. Progenitor Labs is a drug discovery spin-off from Plasticell and recently received £4m in funding from SR One, the corporate venture arm of GlaxoSmithKline (GSK). Cell therapy and regenerative medicine is a focus of SBC’s [...]

June 10th, 2013|Press Releases|

Licenced from Plasticell, EMD Millipore Launches OsteoMAX-XF™, a Fully-defined, Xeno-free Mesenchymal Stem Cell Osteogenic Differentiation Medium

EMD Millipore, the Life Science division of Merck KGaA of Darmstadt, Germany, and Plasticell of London, UK, today announced the availability of OsteoMAX-XF™, the first fully defined, xeno-free human mesenchymal stem cell differentiation medium for the differentiation of mesenchymal stem cells into osteocytes.  Mineralization can be detected in less than one week, whereas competing products that contain serum require approximately [...]

May 9th, 2013|Press Releases|